Growth Stalk Holdings Valuation

Is GSTK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GSTK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GSTK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GSTK's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GSTK?

Key metric: As GSTK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GSTK. This is calculated by dividing GSTK's market cap by their current revenue.
What is GSTK's PS Ratio?
PS Ratio	43x
Sales	US$583.34k
Market Cap	US$25.10m

GSTK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	42.9x
Enterprise Value/EBITDA	-62.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GSTK's PS Ratio compare to its peers?

The above table shows the PS ratio for GSTK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
ETST Earth Science Tech	1.5x	n/a	US$54.5m
KPRX Kiora Pharmaceuticals	0.6x	-15.1%	US$10.1m
FLHL.F Filament Health	5.1x	n/a	US$7.9m
BSEM BioStem Technologies	1.1x	20.1%	US$231.4m
GSTK Growth Stalk Holdings	43x	n/a	US$25.1m

Price-To-Sales vs Peers: GSTK is expensive based on its Price-To-Sales Ratio (43x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does GSTK's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

71 Companies	Price / Sales	Estimated Growth	Market Cap
OGN Organon	0.6x	-0.06%	US$3.94b
PRGO Perrigo	0.9x	3.4%	US$3.83b
BHC Bausch Health Companies	0.3x	1.5%	US$2.93b
AMRX Amneal Pharmaceuticals	1x	5.6%	US$2.60b

71 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: GSTK is expensive based on its Price-To-Sales Ratio (43x) compared to the US Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is GSTK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GSTK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	43x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GSTK's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

6.8%

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

6.1%

14.8%